BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286-94. [PMID: 29113302 DOI: 10.18632/oncotarget.17925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Huang K, Ding X, Tang H, Xu Z. Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway. J Thorac Dis 2019;11:3030-8. [PMID: 31463132 DOI: 10.21037/jtd.2019.07.46] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ying J, Zhang M, Qiu X, Lu Y. The potential of herb medicines in the treatment of esophageal cancer. Biomed Pharmacother. 2018;103:381-390. [PMID: 29674273 DOI: 10.1016/j.biopha.2018.04.088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
3 Abbasi BA, Iqbal J, Ahmad R, Bibi S, Mahmood T, Kanwal S, Bashir S, Gul F, Hameed S. Potential phytochemicals in the prevention and treatment of esophagus cancer: A green therapeutic approach. Pharmacological Reports 2019;71:644-52. [DOI: 10.1016/j.pharep.2019.03.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
4 Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi M, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. Updates Surg 2019;71:599-624. [DOI: 10.1007/s13304-019-00696-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lyu J, Li T, Wang Q, Li F, Diao P, Liu L, Li C, Lang J. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiat Oncol 2018;13:233. [PMID: 30477531 DOI: 10.1186/s13014-018-1183-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Davis LE, Gupta V, Allen-Ayodabo C, Zhao H, Hallet J, Mahar AL, Ringash J, Doherty M, Kidane B, Darling G, Coburn NG. Patient-reported symptoms following diagnosis in esophagus cancer patients treated with palliative intent. Dis Esophagus 2020;33:doz108. [PMID: 31957801 DOI: 10.1093/dote/doz108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li W, Chen P, Zhang N, Song T, Wu S. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study. Oncologist 2019;24:461-e136. [PMID: 30850562 DOI: 10.1634/theoncologist.2019-0119] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K. Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist 2019;24:163-e76. [PMID: 30361422 DOI: 10.1634/theoncologist.2018-0653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]